Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
25-2
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
25-2
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Issue 25-2
News Flashes
advertisement
News Flashes
IGR 25-2
Both low MAP and DAP, when combined with low mean IOP and increased SD, also resulted in steeper MD slopes
The use of portable visual field devices such as virtual reality headsets is still in its infancy and there are presently a wide variety of approaches that are being employed, none of which have been able to achieve the highest degree of compatibility with the methods employed by the Humphrey Field Analyzer
If the results of this pilot study are confirmed, the oxygen consumption of peripheral mononuclear blood cells and the nicotinamide adenine dinucleotide level may become new biomarkers for progressive glaucoma
This study highlights the importance of separating POAG genetics into IOP-dependent and IOP-independent components
Despite greater access to eye care, PACG prevalence was similar to that reported in China, and visual morbidity was strikingly low: only one case of unilateral blindness and none of bilateral blindness, even though three-quarters of PACG cases were previously undiagnosed.
Its clinical relevance remains uncertain, as the role of IOP fluctuation in glaucoma progression is still debated, and recent evidence does not consistently support diurnal or long-term IOP variability as independent predictors of disease progression.
Switching to SLT decreased medication use significantly (from 1.38 to 0.59 mean medications) and allowed 60.5% to attain medication freedom.
IOP measurements obtained by Tono-Vera and ORA were comparable to each other, among patients with and without open angle glaucoma
Issue
25-2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept